Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus

Hepatocellular carcinoma (HCC) has one of highest mortalities globally amongst cancers, but has limited therapeutic options once in the advanced stage. Hepatitis B or C virus infection are the most common drivers for HCC carcinogenesis, triggering chronic liver inflammation and adding to the complex...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonilla, Cecilia Monge, McGrath, Nicole A., Fu, Jianyang, Xie, Changqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597818/
https://www.ncbi.nlm.nih.gov/pubmed/33134550
http://dx.doi.org/10.20517/2394-5079.2020.58
_version_ 1783602448475095040
author Bonilla, Cecilia Monge
McGrath, Nicole A.
Fu, Jianyang
Xie, Changqing
author_facet Bonilla, Cecilia Monge
McGrath, Nicole A.
Fu, Jianyang
Xie, Changqing
author_sort Bonilla, Cecilia Monge
collection PubMed
description Hepatocellular carcinoma (HCC) has one of highest mortalities globally amongst cancers, but has limited therapeutic options once in the advanced stage. Hepatitis B or C virus infection are the most common drivers for HCC carcinogenesis, triggering chronic liver inflammation and adding to the complexity of the immune microecosystem of HCC. The emergence of immunotherapy has afforded a new avenue of therapeutic options for patients with advanced HCC with a history of hepatitis B or C virus infection. This article reviews the change of immunity elicited by hepatitis B or C virus infection, the immune feature of HCC, and the clinical evidence for immunotherapy in advanced HCC and discusses future directions in this field.
format Online
Article
Text
id pubmed-7597818
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-75978182020-10-30 Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus Bonilla, Cecilia Monge McGrath, Nicole A. Fu, Jianyang Xie, Changqing Hepatoma Res Article Hepatocellular carcinoma (HCC) has one of highest mortalities globally amongst cancers, but has limited therapeutic options once in the advanced stage. Hepatitis B or C virus infection are the most common drivers for HCC carcinogenesis, triggering chronic liver inflammation and adding to the complexity of the immune microecosystem of HCC. The emergence of immunotherapy has afforded a new avenue of therapeutic options for patients with advanced HCC with a history of hepatitis B or C virus infection. This article reviews the change of immunity elicited by hepatitis B or C virus infection, the immune feature of HCC, and the clinical evidence for immunotherapy in advanced HCC and discusses future directions in this field. 2020-10-12 2020 /pmc/articles/PMC7597818/ /pubmed/33134550 http://dx.doi.org/10.20517/2394-5079.2020.58 Text en Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Bonilla, Cecilia Monge
McGrath, Nicole A.
Fu, Jianyang
Xie, Changqing
Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
title Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
title_full Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
title_fullStr Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
title_full_unstemmed Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
title_short Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
title_sort immunotherapy of hepatocellular carcinoma with infection of hepatitis b or c virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597818/
https://www.ncbi.nlm.nih.gov/pubmed/33134550
http://dx.doi.org/10.20517/2394-5079.2020.58
work_keys_str_mv AT bonillaceciliamonge immunotherapyofhepatocellularcarcinomawithinfectionofhepatitisborcvirus
AT mcgrathnicolea immunotherapyofhepatocellularcarcinomawithinfectionofhepatitisborcvirus
AT fujianyang immunotherapyofhepatocellularcarcinomawithinfectionofhepatitisborcvirus
AT xiechangqing immunotherapyofhepatocellularcarcinomawithinfectionofhepatitisborcvirus

Ejemplares similares